Cancer cells adapt their metabolic processes to support rapid proliferation, but less is known about how cancer cells alter metabolism to promote cell survival in a poorly vascularized tumour microenvironment [1] [2] [3] . Here we identify a key role for serine and glycine metabolism in the survival of brain cancer cells within the ischaemic zones of gliomas. In human glioblastoma multiforme, mitochondrial serine hydroxymethyltransferase (SHMT2) and glycine decarboxylase (GLDC) are highly expressed in the pseudopalisading cells that surround necrotic foci. We find that SHMT2 activity limits that of pyruvate kinase (PKM2) and reduces oxygen consumption, eliciting a metabolic state that confers a profound survival advantage to cells in poorly vascularized tumour regions. GLDC inhibition impairs cells with high SHMT2 levels as the excess glycine not metabolized by GLDC can be converted to the toxic molecules aminoacetone and methylglyoxal. Thus, SHMT2 is required for cancer cells to adapt to the tumour environment, but also renders these cells sensitive to glycine cleavage system inhibition.
Many inborn disorders of amino acid metabolism lead to severe impairment of the developing nervous system, at least in part through toxic effects on neural stem cells 4, 5 . As brain cancer cells with high tumorigenic potential share characteristics with neural stem cells 6 , we wondered whether they might have similar metabolic vulnerabilities. To begin to test this idea, we identified a set of amino acid catabolism genes whose loss causes developmental brain toxicity (Supplementary Table 1 ) and identified those with elevated expression in glioma compared to normal brain (Supplementary Table 2 ). This analysis yielded seven genes (Fig. 1a) , and we focused on glycine decarboxylase (GLDC) because its expression was also highly enriched in neural stem cells (Fig. 1a) . Previous work shows that elevated GLDC expression in non-small cell lung cancer tumour initiating cells promotes oncogenesis by upregulating pyrimidine biosynthesis 7 . GLDC codes for the central component of a four-protein complex (glycine cleavage complex) that catalyses the degradation of glycine into ammonia, carbon dioxide, and a methylene unit that enters the folate pool, and its loss causes nonketotic hyperglycinaemia, a disorder that severely affects the developing brain 5, 8 . Consistent with the bioinformatic analysis, GLDC protein was highly expressed in tumorigenic 9,10 glioblastoma-derived neurosphere-forming cell lines BT145 and 0308, but not in their differentiated, non-tumorigenic counterparts (Extended Data Fig. 1a-c) . RNA interference-mediated inhibition of GLDC caused loss of viability and breakdown of neurospheres, but did not affect the differentiated cells (Fig. 1b, Extended Data Fig. 1d and e). GLDC suppression was also toxic to LN229 cells, an adherent glioblastoma multiforme (GBM) cell line. Thus, loss of GLDC function has toxic consequences on a subset of GBM cell lines in culture.
We hypothesized that loss of GLDC may lead to the accumulation of toxic amounts of glycine. Indeed, in LN229 cells GLDC suppression raised the levels of intracellular glycine (Fig. 1c) , as has been observed in the plasma in nonketotic hyperglycinaemia 5 . Interestingly, esterified glycine, which readily crosses cellular membranes and is processed into glycine 11 , caused dose-dependent toxicity to the cells while other esterified amino acids did not (Fig. 1d) , and this toxicity was reduced by overexpression of GLDC (Extended Data Fig. 1f ).
To understand why excess glycine may be toxic to cells, we considered possible alternative fates for glycine not degraded by GLDC, its primary route of catabolism. Based on the KEGG database, there are at least 17 metabolic enzymes that process glycine, and thus we examined whether disruption of any of these other metabolic routes may affect cell sensitivity to GLDC suppression, using a pooled short hairpin RNA approach (Extended Data Fig. 2a-c) . We found that suppression of glycine C-acetyltransferase (GCAT) protects against the toxicity of GLDC knockdown (Fig. 1f, Extended Data Fig. 2c, d ). GCAT is part of a pathway that interconverts glycine and threonine in the mitochondria 12, 13 ( Fig. 1e ) via 2-amino-3-ketobutyrate, an unstable intermediate that is spontaneously decarboxylated to form the toxic pro-oxidant metabolite aminoacetone 14 , which itself is readily metabolized to methylglyoxal, a toxic, highly reactive aldehyde implicated in the pathology of diabetes and other disorders 15 . This raised the possibility that the glycine that is metabolized by GCAT, instead of GLDC, can be converted to aminoacetone and methylglyoxal. Indeed, GLDC knockdown or esterified glycine overload led to aminoacetone formation in LN229 cells grown in culture or as a xenografted tumour (Fig. 1g-i , Extended Data Fig. 2e, f) . GLDC knockdown also increased methylglyoxal levels, as indicated by increases in argpyrimidine, a methylglyoxal-derived advanced glycation end product (Fig. 1j, Extended Data Fig. 2g ). Importantly, these changes were suppressed by silencing of GCAT (Fig. 1k, Extended Data Fig. 2i ). Thus glycine accumulation is deleterious, at least in part because it is converted via GCAT to aminoacetone and methylglyoxal when not sufficiently catabolized by GLDC. Recent work shows that, in the absence of serine, large quantities of glycine can be toxic by causing a depletion of the one-carbon pool that is rescued by formate supplementation 16 . Formate does not rescue glycine toxicity under our conditions (data not shown), showing that additional toxicities from excess glycine beyond depletion of one-carbon units contribute to the deleterious effects of GLDC inhibition in these cells.
To more rigorously test the idea that GLDC inhibition impairs cell viability by causing the accumulation of glycine, we suppressed the upstream enzyme serine hydroxymethyltransferase (SHMT2) (Extended Data Fig. 3a) . While SHMT2 is a mitochondrial enzyme that converts serine to glycine and acts as a key source of glycine in proliferating cells, the cytoplasmic SHMT1 enzyme does not signifi-cantly contribute to glycine production 17, 18 . Consistent with SHMT2 functioning upstream of GLDC, suppression of SHMT2 (Extended Data Fig. 1g ) decreased both net serine consumption and glycine production in LN229 cells (Fig. 2a) and completely prevented glycine cleavage activity in isolated mitochondria as measured by [ 14 C]CO 2 release (Extended Data Fig. 3a, b) . Importantly, the pre-emptive knockdown of SHMT2 protected BT145, LN229 and U251 (a GBM line) cells against the detrimental effects of GLDC knockdown (Fig. 2b, 
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Overlapping genes Genes overexpressed in brain tumours (Extended Table 2) Genes underlying metabolic disorders with developmental brain toxicity (Extended Table 1 with 1 mM esterified (e-) leucine or glycine for 3 days. h, Volumes of xenografts formed from LN229 cells expressing shGFP (n 5 5), shGLDC dox (n 5 8) or shGLDC dox plus shRNA-resistant GLDC (n 5 8). Tumours were allowed to form for two weeks before doxycycline induction (Methods). Volumes are shown as relative to the starting volume (at beginning of induction) for each tumour. Error bars are s.e.m. i, Aminoacetone levels, normalized to tumour weight, from xenograft tumours shown in h, n 5 4 per group. Error bars are s.d. j, Immunoblots from xenograft tumours shown in h. Methylglyoxal levels are indicated by argpyrimidine antibody, which recognizes proteins modified by methylglyoxal. k, Aminoacetone levels in cells stably transduced with Cas9 and single guide RNA against GCAT or control (GFP), and treated (4 days and 2 days before collection) with 1 mM esterified leucine or glycine. For b, c, d, f, g and k, n 5 3 independent biological replicates; For h and i, each n described refers to the number of xenografts. For all panels. *P , 0.05 (Student's t-test). Data Fig. 3d-f) . These results strongly suggest that the toxicity caused by GLDC suppression is due to an accumulation of the GLDC substrate glycine instead of the depletion of 5,10-methylenetetrahydrofolate (5,10-MTF) and NADH, metabolites produced by the glycine cleavage reaction (Extended Data Fig. 3a) . Furthermore, this may explain why the differentiated BT145 and 0308 cells, which express low levels of SHMT2 (Extended Data Fig. 1h, i) , are insensitive to suppression of GLDC. In a panel of cancer cell lines, we found a marked correlation between SHMT2 expression levels and sensitivity to GLDC silencing ( Fig. 2d and e and Extended Data Fig. 3g, h ), a pattern that also matched their intracellular glycine accumulation (Fig. 2f) . Collectively, these findings reveal a conditionally lethal relationship between SHMT2 and GLDC, in which SHMT2-mediated production of glycine necessitates its clearance by GLDC so as to prevent its conversion to toxic metabolites such as aminoacetone and methylglyoxal (Fig. 2g) . As seen in the panel of cell lines, this relationship is probably relevant across multiple cancer cell types and is not limited to GBM cells. In contrast to the toxic effects of GLDC knockdown, knockdown of SHMT2 did not affect the proliferation or survival of multiple cell lines under normal culture conditions (Extended Data Fig. 3i ). Furthermore, SHMT2 was not necessary for the proliferation or self-renewal of neurosphere-forming cells (Extended Data Fig. 1j-l) . As it seemed unlikely that cancer cells would obtain high SHMT2 expression if it did not provide a benefit, we considered that SHMT2 might have a context-dependent role and examined SHMT2 and GLDC expression in sections of human GBM tumours. In normal brains SHMT2 and GLDC expression was not detected in most cells but was at low levels in astrocytes and vessels (Fig. 3a, Extended Data Fig. 4a, d, e) . In GBM tumours, however, both SHMT2 and GLDC were expressed at high levels (Fig. 3a , Extended Data Fig. 4a, d and e) that even allowed the detection of individual cancer cells migrating into the brain parenchyma (Extended Data Fig. 4b and c) . Interestingly, the highest levels of SHMT2 and GLDC expression were distinct bands surrounding necrotic and acellular regions, highlighting cells of what is referred to as the pseudopalisading necrosis (Fig. 3a-c , Extended Data Fig. 4a, f, g ). This feature, which is unique to glioblastomas, consists of a dense layer of ''pseudopalisading'' viable cells that outline an ischaemic tumour region which is thought to form upon the collapse or occlusion of an intratumoral vessel 19 . The expression of SHMT2 in ischaemic tumour zones suggested that it might have a key role in cells in environments with limited oxygen or nutrient levels. Indeed, under hypoxic conditions (0.5% oxygen), SHMT2 suppression impaired and SHMT2 overexpression enhanced LN229 cell proliferation (Fig. 3d, Extended Data Fig. 4i ). As these effects were relatively modest, we set out to more closely recapitulate conditions of tumour ischaemia by using a previously described rapid xenograft model 20 . In this heterotopic model, a large bolus of cells is injected subcutaneously and the tumour collected before angiogenesis. Thus, the tumour core experiences oxygen and nutrient deprivation, which frequently results in extensive cell death, while the outermost regions of the tumour receive sufficient oxygen and nutrients and are completely viable (Fig. 3e) . In such xenografts, LN229 cells, which express high levels of SHMT2 (Fig. 2d) , formed a tumour with a heterogeneous central region that contained both dying cells (labelled by cleaved-PARP) and numerous 'islands' of viable cells lacking cleaved PARP (Fig. 3f, g ). On the other hand, tumours formed from LN229 cells expressing a SHMT2 shRNA had a uniformly barren, cleaved-PARP immunoreactive central region that was almost completely devoid of any surviving cells. Importantly, overexpression of an RNAi-resistant SHMT2 complementary DNA (cDNA) not only rescued the effects of SHMT2 knockdown, but also had a strong protective effect, in some cases resulting in central tumour regions that were almost entirely viable (Fig. 3f, g ). While this model does not directly mimic pseudopalisading necroses, it indicates that SHMT2 expression is an important determinant of cancer cell survival within an ischaemic tumour context.
To begin to understand why this might be, we surveyed the metabolic consequences of SHMT2 suppression in LN229 cells. Quantitative central carbon metabolism profiling revealed that, in addition to the expected accumulation of serine and depletion of glycine, SHMT2 suppression increased the levels of tricarboxylic acid (TCA) cycle intermediates and decreased those of the pentose phosphate pathway (Extended Data Fig. 5a ). SHMT2 suppression also increased cellular oxygen consumption (Extended Data Fig. 5b ), which may reflect increased TCA 
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cycle activity driving NADH into the oxidative phosphorylation pathway. Furthermore, untargeted metabolite profiling identified AICAR (5-amino-1-b-D-ribofuranosyl-imidazole-4-carboxamide), SAICAR (succinylaminoimidazolecarboxamide ribose-5-phosphate) and fructose bisphosphate (FBP) as amongst the most highly elevated metabolites (Fig. 4a and Supplementary Tables 6 and 7 ). The increase in the sequential intermediates SAICAR and AICAR can be explained because 10-formyltetrahydrofolate, a downstream product of SHMT2 and SHMT1 activity, is required for the conversion of AICAR to FAICAR during de novo purine biosynthesis (Extended Data Fig. 5d ). While a link between SHMT2 and FBP is less clear, we nonetheless noted that the suppression of SHMT2 significantly increases levels of all three known activators of pyruvate kinase isoform M2 (PKM2)-serine, FBP and SAICAR [21] [22] [23] -raising the possibility that SHMT2 antagonizes PKM2 activity by decreasing the levels of its activators.
Pyruvate kinase catalyses the conversion of phosphoenolpyruvate to pyruvate in glycolysis, and PKM2 is the isoform associated with proliferating cells 1, 2 . PKM2 has regulated activity, unlike the constitutively active PKM1. Decreasing PKM2 activity can allow redistribution of glycolytic carbons in a manner advantageous for cancer cell proliferation in tumours 3, 24, 25 , and either pharmacological PKM2 activation or PKM1 expression can impair tumour growth 25, 26 . Consistent with the increase in metabolites known to activate PKM2 (Figs. 2a and 4a), PKM2 activity was significantly increased in cells with suppressed SHMT2, despite no change in PKM2 protein levels (Fig. 4b , Extended Data Fig. 5c ). To determine whether SHMT2 silencing induces changes in central carbon metabolism that are consistent with increased pyruvate kinase (PK) activity, we measured kinetic flux through glycolysis in live cells using C labelling rate of pyruvate, the product of PKM2, was elevated in cells with suppressed SHMT2, indicating increased PKM2 activity, which was also confirmed in cells overexpressing PKM2 (Fig. 4c) . By calculating the sum 13 C labelling of lactate, citrate and alanine, the major downstream fates of pyruvate 27 , we estimate that the total pyruvate kinase flux is increased by ,70% following SHMT2 knockdown (Extended Data Fig. 5e-g ). Furthermore, these changes as well as changes in metabolite levels and oxygen consumption were suppressed by overexpression of an RNAi-resistant SHMT2 cDNA (Fig. 4c , Extended Data Fig. 5e ), arguing against off-target RNAi effects. These results support a model in which SHMT2 suppression leads to increased pyruvate kinase activity and carbon flux into the TCA cycle, while cells that express high levels of SHMT2 limit PKM2 activity and flux into the TCA cycle (Fig. 4d) . This may confer a survival benefit in ischaemic tumour contexts, as it has been shown that limiting pyruvate entry into TCA cycle, and thus limiting oxygen consumption, provides a survival advantage under hypoxia 28 . If the effects of SHMT2 on oxygen consumption and survival within an ischaemic microenvironment occur via suppression of PKM2 activity, then forced activation of PKM2 should antagonize these effects. Indeed, either overexpression of PKM2 or the addition of the PKM2 product pyruvate to the media increased the oxygen consumption rate in LN229 cells to the equivalent levels observed following SHMT2 knockdown ( Fig. 4e and Extended Data Fig. 5i) . Thus, pyruvate kinase activity may be a determinant of oxygen consumption in these cells. Furthermore, overexpression of PKM2, or the pharmacological activation of PKM2 using TEPP-46 or DASA-58 (ref. 26), reduced LN229 survival in 0.5% hypoxia to a similar extent as SHMT2 suppression (Extended Data Fig. 5j ). Finally, in the rapid xenograft model, PKM2 overexpression, like SHMT2 loss, reduced the survival of LN229 cells (Fig. 4f, g ). These findings support a model in which high SHMT2 expression rewires metabolism to suppress PKM2 activity and promote survival in the ischaemic tumour environment (Extended Data Fig. 5k ).
In summary, we identified toxic glycine accumulation following loss of GLDC as a metabolic liability in cells expressing high levels of SHMT2. Thus, in nonketotic hyperglycinaemia, preventing endogenous glycine production via SHMT2 inhibition may be the desired route of therapy, as current treatment options targeting exogenous glycine, such as dietary restriction or plasma glycine conjugation, are largely ineffective 5 . On the other hand, SHMT2 is elevated in a subset of cancer cells and promotes changes in metabolism that allow cells to survive in an ischaemic tumour microenvironment. It is observed that hypoxia/ischaemia selects for cancer cells with increased tumorigenicity and therapyresistance, and manifestations of tumour ischaemia, such as pseudopalisading necrosis, are associated with poor prognoses 29 . Thus, our (shGFP, n 5 10; shSHMT2_1, n 5 8; shGFP1PKM2 cDNA, n 5 10; shSHMT2_1 1 PKM2 cDNA, n 5 6; each n described refers to the number of xenografts). For a, b and c, n 5 3 independent biological replicates; error bars are s.d. For all panels, *P , 0.05 (Student's t-test).
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findings raise the possibility that GLDC inhibition may be exploited to specifically target malignant and refractory subpopulations of cells expressing high levels of SHMT2.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 19 , provided by H. Fine and K. Ligon, and maintained as tumorigenic neural stem cell-like neurospheres in NBE medium (neurobasal medium containing N-2 and B-27 supplements, epidermal growth factor, basic fibroblast growth factor, L-glutamine, and penicillin-streptomycin) as described 10 . When passaging, spheres were manually broken into smaller spheres and single cells by trypsinization and pipetting. For differentiation experiments, neurospheres were broken into single cells and grown in DMEM (containing 10% inactivated fetal bovine serum and penicillin-streptomycin) for at least 1 week.
All other cell lines (LN229, ACHN, A2058, U251, T47D, MCF7, HMC-1-8, U87, DoTc2-4510, and PC3) were obtained from Broad Institute Cancer Cell Line Encyclopedia, and cultured as adherent cell lines in DMEM with exceptions noted below. Cell lines were verified to be free of mycoplasma contamination. Cell line origins are as follows: 0308, BT145, BT112, LN229, U251, U87 (glioblastoma), ACHN (renal cell adenocarcinoma), A2058 (melanoma), T47D (breast ductal carcinoma), MCF7 (breast pleural effusion), HMC-1-8 (breast pleural effusion), DoTc2-4510 (cervical carcinoma), PC3 (prostate adenocarcinoma). When comparing SHMT2 protein expression across cell lines, all cell lines were grown in NBE for 2 days before collection in order to be grown under identical conditions. For experiments measuring oxygen consumption and for untargeted metabolite profiling experiments, RPMI was used, which does not contain the PKM2 product pyruvate. Subcutaneous xenograft experiments. For regular subcutaneous xenograft studies, LN229 cells were transduced to stably express shRNAs (shGLDC dox , shGFP via puromycin selection for 3 days) and then cDNAs (empty vector or RNAi-resistant GLDC cDNA via blasticidin selection for 3 days) then further amplified. Xenografts were initiated with 3 million cells injected subcutaneously per site, with 30% Matrigel, 100-ml injection volume in the left and right flanks of female, 6-8 week old NCr nude mice (Taconic). Tumours were allowed to form for two weeks, and at this point the first caliper measurements were taken, and induction started by addition of doxycycline at 2 g l 21 to drinking water. Tumour volume was calculated using the modified ellipsoid formula K(length 3 width 2 ) and expressed as relative fold change to the initial volume of each tumour at the start of doxycycline induction.
For rapid tumour xenograft studies to form ischaemic tumour cores, LN229 cells were transduced to stably express both cDNAs (empty vector, RNAi-resistant SHMT2 cDNA, or PKM2 cDNA via blasticidin selection) and shRNAs (via puromycin selection). Xenografts were initiated with 8 million cells injected subcutaneously per site in the left and right flanks of female, 6-8-week-old NCr nude mice (Taconic). Tumours were removed at 48 h post-injection and fixed in 10% formalin.
For the quantification of viable and nonviable regions in the ischaemic region, fixed tumours were embedded and sections prepared. Sections were immunostained for SHMT2 and cleaved PARP, and images of the central tumour regions were obtained using a Zeiss Axiovert 200M inverted fluorescent microscope and AxioVision Software. All images were acquired and processed under the same parameters across the entire set. The image labels were scrambled so that analyses could be carried out in a blinded manner, and the Red channel (cPARP) and Blue channel (Hoechst 33342) was analysed. Using Adobe Photoshop, the entire central necrotic region, labelled by cleaved PARP, was manually outlined with the Lasso tool. Within this tumour region, the total area counts (in pixels) of the dead (cPARP positive and Hoechst positive) and viable (cPARP negative and Hoechst positive) regions were obtained to calculate the percentage of viable region within the central necrotic zone.
Analyses of oncogenomic and other microarray data. We had previously classified a set of 2,752 metabolic enzymes and transporters 32 . To obtain a list of metabolic genes and transporters that have increased expression in gliomas, we analysed the 9 expression studies deposited in Oncomine 33 that profiled gene expression normal brain tissue and gliomas. For each data set, the top 10% of genes overexpressed in the glioma relative to normal brain was obtained, and cross referenced with our gene set, which yielded a list of 367 genes which placed within the top 10% of overexpressed genes in at least two separate studies.
To determine the expression of selected metabolic genes in the context of neural stem cells, we analysed a set of 5 microarray data sets deposited in Gene Expression Omnibus in which neural stem cells are compared with differentiated controls (GSE 36484, GSE10721, GSE15209, and two comparison groups in GSE11508). A summary of the data sets and fold change in expression of each gene in each study is provided in Supplementary Table 3 . shRNA expressing lentivirus generation and sequences. For each gene of interest (GLDC, SHMT2, GCAT, GCSH), 5 lentiviral shRNA constructs were obtained from The RNAi Consortium (TRC) and recombinant lentivirus containing supernatant was produced using a transient transfection protocol 34 . Each lentivirus was separately transduced into LN229 by overnight incubation of virus in trypsin dissociated cells (20,000 cells per ml, 2 ml into each well of a 6-well plate) in the presence of polybrene. Lentiviral expression of shGFP and shLacZ served as negative controls for gene knockdown, and noninfected cells served as negative controls for transduction. Cells were selected with puromycin for 3 days to ensure transduction, and for each gene, the two (or three) most effective shRNAs, in terms of knockdown of protein expression by western blot, were chosen for use in our experiments.
The following shRNA sequences were used: shGFP: TRCN0000072186, target sequence: TGCCCGACAACCACTACCTGA; shLacZ: TRCN000007 2235, target sequence: CCGTCATAGCGATAACGAGTT; shGLDC_1: TRCN0000036599, target sequence: CGAGCCTACTTAAACCAGAAA; shGLDC_2: TRCN0000036603, target sequence: GAAGTTTATGAGTCTCC ATTT; shGLDC dox : target sequence same as shGLDC_2, cloned into doxycycline-inducible vector (pLKO_GC11); shSHMT2_1: TRCN0000238795, target sequence: CGGAGAGTTGTGGACTTTATA; shSHMT2_2: TRCN0000034804, target sequence: CCGGAGAGTTGTGGACTTTAT; shSHMT2_3: TRCN 0000234657, target sequence: GTCTGACGTCAAGCGGATATC; shGCSH_1: TRCN0000083395, target sequence: GTGAACTCTATTCTCCTTTAT; shG-CSH_2: TRCN0000428788, target sequence: TGAGGAACACCACTATC TTAA; shGCAT_1: TRCN0000034579, target sequence: CCTTAACTT CTGTGCCAACAA; shGCAT_2: TRCN0000034580, target sequence: CCAG AGGTTCCGTAGTAAGAT; shNOTCH2_1: TRCN0000004896, target sequence: CCAGGATGAATGATGGTACTA; shNOTCH2_2: TRCN0000 004897, target sequence: CCACACAACAACATGCAGGTT. Cell viability assays with shRNA transduction. For cell viability experiments involving transduction of a single shRNA (for example, shGLDCs), cell lines (neurosphere-forming cell lines, LN229, ACHN, A2058, U251, T47D, MCF7, HMC-1-8, U87, DoTc2-4510, and PC3) were seeded in 96-wells at 3,500 to 5,000 cells per well. The next day, neurosphere-forming lines were infected with lentivirus and polybrene via 30-min spin at 2,250 r.p.m. followed by incubation for 1 h before a media change (due to neurosphere-forming cell line sensitivity to prolonged incubation with virus and polybrene), while all the non neurosphere cell lines were infected via overnight incubation of virus and polybrene before a media change. For all nonneurosphere cell lines, puromycin selection was started 24 h after infection, while for the neurosphere lines it was started 48 h after infection (because of their sensitive nature). Cells were incubated for 4-6 additional days as indicated, and overall cell viability was quantified using the Cell Titer Glo (CTG) reagent (Promega) and measuring luminescence. As doubling times and luminescence values per viable cell differ between different cell lines, values are normalized to the same cells transduced in parallel with innocuous shGFP hairpins as indicated.
When comparing sensitivity to GLDC (or GCSH, SHMT2) knockdown across different cell lines, two identical sets of experiments, one which receives puromycin selection and one which does not, were carried out in parallel. Comparing the two ensures that the toxicity observed in the 'sensitive' cell lines is due to GLDC knockdown and not due to selection of nontransduced cells, because identical toxicity is also seen in the nonselected plate. Conversely, we can ensure that low toxicity observed in the 'insensitive' cell lines is not an artefact of poor transduction because if they had been poorly transduced, then toxicity would be observed in the puromycin selected plate. In this manner, we verified full transduction of cells that we have examined for GLDC effects on viability.
For some experiments, cells are transduced with more than one shRNA and this was carried out in a sequential manner. Cells were infected with the first lentivirus expressing an shRNA (shGFP, shSHMT2_1, or shSHMT2_2, shGCAT_1, shGCAT_2) as described, then selected in puromycin for 3 days, and expanded for 2-5 more days. Equal numbers of each stable cell line were infected with the second lentivirus (shGFP,
shGLDC_1, or shGLDC_2), seeded in 96-well plates, and at 5 days following infection, cell viability was measured. Because in some cases (for example, shGCAT hairpins) the primary transduction itself moderately impairs cell proliferation, viability values for the cells secondarily transduced with shGLDCs are always expressed as relative to the same primary transduced cells, processed in parallel, which are secondarily infected with a control hairpin (shGFP). Because the secondary transduction cannot be selected for (since the cells are already puromycin resistant from the first round of transduction), effective knockdown of the second gene was verified by western blot.
For cell proliferation experiments, cell counts were determined using a Coulter counter (Beckman). CRISPR-Cas9 mediated gene knockdown. In some of our experiments, effective gene knockdown was achieved via CRISPR/Cas-9 mediated genome editing. We used pLENTICRISPR, in which both single guide RNA, directed against a target of interest, and the Cas9 endonuclease are both delivered to cells via lentivirus 35 in an analogous manner to the TRC shRNA experiments. Three target site sequences, selected based on best scores as previously calculated for all genes 36 , were cloned into pLENTICRISPR. As described for TRC shRNA transduction, lentiviruses were produced and transduced into trypsin dissociated LN229 cells, via overnight incubation with polybrene. Following media change and puromycin selection, cells were harvested 7 days following infection, and gene knockdown determined by western blotting. The two most effective target guide sequences, in terms of knockdown of protein expression by western blot, were chosen for use in our experiments.
The following target site sequences, transduced via pLENTICRISPR, were used: sgGFP: TGAACCGCATCGAGCTGAAG (plus strand) sgGLDC_1: CGGGACAGCAGCAGTGGCGG (minus strand) sgGLDC_2: ATTTGGGGTAGACATCGCCC (minus strand) sgGCAT_1: CCAGCGCTGACTGTGCGCGG (minus strand) sgGCAT_2: GAAGCATCGGCTGCGCCTGG (plus strand) Pooled shRNA screening. pLKO.1 lentiviral plasmids encoding shRNAs targeting glycine metabolizing enzymes, metabolic enzymes for other amino acids, as well as nontargeting controls were obtained and combined to form a pool as described in Extended Fig. 2 . This pool was used to generate a pool of lentiviruses as described 34 . LN229 cells were infected with the pooled virus at a low titre (multiplicity of infection of 0.7) to ensure that each cell contained only one viral integrant. After cells were selected for 3 days with puromycin, pooled cells were dissociated, divided, and subjected to a secondary infection with either shGFP, shGLDC_1, or shGLDC_2. After 6 days following the secondary infection, a time point corresponding to moderate toxicity as determined by decreased proliferation and moderate changes cell morphology compared to shGFP infected cells, cells were collected to obtain genomic DNA. As previously described 32 , the shRNAs encoded in the genomic DNA were amplified and analysed by high throughput sequencing (Illumina) using the following primers:
Barcoded forward primer ('N's indicate location of sample-specific barcode sequence): AATGATACGGCGACCACCGAGAAAGTATTTCGATTTCTTGG CTTTATATATCTTGTGGAANNGACGAAAC; Common reverse primer: CA AGCAGAAGACGGCATACGAGCTCTTCCGATCTTGTGGATGAATACTG CCATTTGTCTCGAGGTC. Illumina sequencing primer: AGTATTTCGATT TCTTGGCTTTATATATCTTGTGGAA.
Sequencing reads were deconvoluted using GNU Octave software as described. For each shRNA, Abundance was defined as (number of reads/total number of all reads of pooled cells in either shGFP or shGLDC). Enrichment was defined as (abundance in shGLDC / abundance in shGFP), thus an enrichment score of 2.0 would indicate that an shRNA is twice as abundant in the shGLDC infected pool as it was in the shGFP infected pool. Fold change is defined as the enrichment score of an shRNA relative to the mean enrichment score of all 11 nontargeting control shRNAs. For a given gene, the mean fold change (shGLDC_1/shGFP and shGLDC_2/shGFP) was calculated from all shRNAs targeting that gene. Clonogenic neurosphere formation assay. 0308 cells were stably transduced with shRNAs as indicated, and seeded at single cell-per-well density in poly-D-lysine coated 384-well plates (Becton Dickinson). Wells containing a single cell were marked and two weeks later, the marked wells containing spheres were counted. Histology and immunohistochemistry. Immunohistochemical analyses were performed on discarded archival biopsy (7) and autopsy (7) specimens of glioblastoma, World Health Organization Grade IV, seen at the Departments of Pathology, Massachusetts General Hospital and NYU Langone Medical Center, from 2010 to 2013. Approval from respective Institutional Review Board was obtained, and because we used discarded tissue only, a waiver of informed consent was received. Formalin-fixed, paraffin-embedded brain biopsy tissues were stained with routine haematoxylin and eosin stain (H&E), and cases were reviewed by a neuropathologist (M.S.) to select the most representative block/s for immunohistochemical analysis. Paraffin sections of GBM tumours and normal brains, fixed in 10% formalin, were subjected to deparaffinization and antigen retrieval with Borg Decloaker RTU solution pressurized Decloaking Chamber (Biocare Medical). Antibodies were diluted in in 4% horse serum and 0.1% tween in PBS, which was also used for blocking. Vectastain ABC immunoperoxidase detection kit (Vector Labs) and DAB1 substrate kit (Dako) was used for chromogenic labelling. It was noted that antigen presentation for SHMT2 was much weaker in autopsy sections compared to tumour biopsy sections, likely a result of post-mortem interval, and thus a more concentrated primary antibody incubation and longer chromogenic development was required for these sections to get comparable signal to the biopsy sections.
Images were acquired using an Olympus BX41microscope and CellSens R software. For immunofluorescence staining of GBM tumours and normal brains, as well as rapid tumour xenografts, fixed in 10% formalin, the same deparaffinization, antigen retrieval, and blocking/antibody incubation steps were used as above. Immunoreactivity was detected using Alexa-fluor 488 and 568 antibodies and nuclei labelled with Hoechst 33352 (Life Technologies), and Prolong R Gold antifade reagent (Life Technologies) was used as mounting medium. Images were acquired using a Zeiss Axiovert 200M inverted fluorescent microscope and AxioVision Software. For all image-based data, acquisition and processing steps were carried out using the same parameters across the entire set, aside from the increased antibody concentration and longer chromogenic development for the set of autopsy sections for SHMT2 immunostaining as described. Amino acid analyses. Intracellular amino acids were extracted by hot water extraction, and proteins were removed with sulfosalicylic acid. The amino acids were separated by high-resolution ion-exchange chromatography and derivatized with ninhydrin, and analysed on a Hitachi L-8800 amino acid analyser 37 . Amino acids were normalized by wet pellet weight of the cells before extraction. Quantitative CE-MS based metabolite profiling. Capillary electrophoresis mass spectrometry-based targeted quantitative analysis was performed on stably transduced LN229 cells, as previously described 38 . A total of 116 metabolites involved in glycolysis, pentose phosphate pathway, tricarboxylic acid (TCA) cycle, urea cycle, and polyamine, creatine, purine, glutathione, nicotinamide, choline, and amino acid metabolism were analysed and listed in Supplementary Table 5 . Metabolite extraction and LC-MS analysis. Untargeted metabolite profiling, flux experiments, and amino acetone measurements were performed on a Dionex UltiMate 3000 ultra-high performance liquid chromatography system coupled to a Q Exactive benchtop Orbitrap mass spectrometer, which was equipped with an Ion Max source and a HESI II probe (Thermo Fisher Scientific). External mass calibration was performed every 7 days.
For untargeted metabolite profiling and flux experiments, polar metabolites were extracted from cells growing in a 6-well dish using 400 ml of ice cold 80% methanol with 20 ng ml 21 valine-d8 as an internal extraction standard. After scraping the cells, 400 ml of chloroform was added before vortexing for 10 min at 4 uC, centrifugation for 10 min at 4 uC at 16,000g, and drying 150 ml of the upper methanol/water phase under nitrogen gas. Dried samples were stored at 280 uC then resuspended in 40 ml 50% acetonitrile/50% water immediately before analysis. Cells were usually left plated for 24-48 h after a media change before extraction in order to allow for media conditioning. Accordingly, U-[ 13 C]glucose labelling of cells was achieved by adding a concentrated stock to glucose-free RPMI media to a final concentration of 11.1 mM after 24 h of media conditioning. Chromatographic separation was achieved by injecting 10 ml of sample on a SeQuant ZIC-pHILIC Polymeric column (2.1 3 150 mm 5 mM, EMD Millipore). Flow rate was set to 100 ml per min, column compartment was set to 25 uC, and autosampler sample tray was set to 4 uC. Mobile Phase A consisted of 20 mM ammonium carbonate, 0.1% ammonium hydroxide. Mobile Phase B was 100% acetonitrile. The mobile phase gradient (%B) was as follows: 0 min 80%, 5 min 80%, 30 min 20%, 31 min 80%, 42 min 80%. All mobile phase was introduced into the ionization source set with the following parameters: sheath gas 5 40, auxiliary gas 5 15, sweep gas 5 1, spray voltage 5 23.1kV or 13.0kV, capillary temperature 5 275 uC, S-lens RF level 5 40, probe temperature 5 350 uC. In experiments to measure steady-state levels, metabolites were monitored using a polarity-switching full-scan method. In experiments using U-[ 13 C]glucose tracing, metabolites were monitored using a targeted selected ion monitoring (tSIM) method in negative mode with the quadrupole centred on the M-H ion m11.5, m12.5, or m13.5 mass with a 8 a.m.u. isolation window, depending on the number of carbons in the target metabolite. Resolution was set to 70,000, full-scan AGC target was set to 10 6 ions, and tSIM AGC target was set to 10 5 ions. For tracing experiments, samples were collected at various time points as indicated. Labelling rate was calculated from counts at 6 min, and detailed methods for determining the labelling rate and overall flux are provided in the first three worksheets of Supplementary Table 8. Data were acquired and analysed using Xcalibur v2.2 software (Thermo Fisher Scientific). Full-scan untargeted data was analysed using Progenesis CoMet v2.0 software (Nonlinear Dynamics) to identify differential peaks (Supplementary Table 4 and 5) and the identified metabolites with greatest predicted change were further analysed with Xcalibur. Retention times for selected metabolites appearing in the untargeted analyses (AICAR and SAICAR) were confirmed by running a standard. All standards were obtained commercially, except for SAICAR, which was synthesized enzymatically from AICAR and purified by ionexchange chromatography as described 23 .
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G2015 Macmillan Publishers Limited. All rights reserved Derivatization and LC-MS detection of aminoacetone. The protocol for aminoacetone derivatization with fluorenylmethyl chloroformate (FMOC-Cl) and subsequent detection via LC-MS was adapted from previous studies 39, 40 . LN229 cells grown in 6-cm plates were quickly washed in cold PBS, then extracted with scraping in 500 ml acetonitrile containing 1 mM ethylamine as an internal control for sample recovery and derivatization efficiency. Following vortexing, centrifugation, and transfer of supernatant to eliminate insoluble material, potassium borate buffer at pH 10.4 (final concentration 33 mM) and FMOC-Cl (final concentration 400 mg ml 21 ) were added. Samples were completely dried, 100 ml of water added followed by addition of 800 ml hexane. Following vortexing and centrifugation, the upper phase was transferred to a new tube, dried, and the pellet extracted in acetonitrile.
For LC separation, 10 ml of each biological sample was injected onto an Ascentis Express C18 2.1 3 150 mm (2.7-mm particle size) column (Sigma-Aldrich). Mobile phase A was 0.1% formic acid and mobile phase B was 0.1% formic acid in acetonitrile. The chromatographic gradient was as follows, all at a flow rate of 0.25 ml min 21 : 0-2 min: hold at 5% B; 2-20 min: increase linearly to 75% B; 20-20.1 min: increase linearly to 95% B; 20.1-24 min: hold at 95% B; 24-24.1 min: decrease linearly to 5% B; 24.1-28 min: hold at 5% B. The autosampler was held at 4 uC and the column compartment was held at 35 uC. To minimize carryover, blank injections were performed after every six analytical runs.
All mobile phase was introduced into the ionization source with the spray voltage set to 13.0 kV and the same temperature and gas parameter settings as described in the previous section. The MS data acquisition was performed by tSIM of aminoacetone-FMOC and ethylamine-FMOC (internal standard) with the resolution set at 70,000, the AGC target at 10 5 , the maximum injection time at 150 ms, and the isolation window at 1.0m/z. The full scan range was 150-2,000m/z. Quantitation of the data was performed with Xcalibur v2.2 using a 5 p.p.m. mass tolerance by a researcher (E.F.) blinded to the identity of the samples.
Peak areas for aminoacetone-FMOC were normalized to peak areas for ethylamine-FMOC from the same sample, and further normalized to total protein (mg) and expressed relative to the control sample. Oxygen consumption measurements. Oxygen consumption of LN229 cells was measured using an XF24 Extracellular Flux Analyzer (Seahorse Bioscience). 60,000 cells were plated per well the night before the experiments, and RPMI 8226 media (US Biological 9011) containing 2 mM glutamine and 10 mM glucose without serum was used as the assay media. Oxygen consumption measurements were normalized based on protein concentration obtained from the same plate used for the assay. Lactate dehydrogenase (LDH)-linked pyruvate kinase activity assay. Concentrated (5-10 mg ml 21 ) hypotonic lysate was prepared from cells by swelling on ice for 10 min in one equivalent of 13 hypotonic lysis buffer (20 mM HEPES pH 7.0, 5 mM KCl, 1 mM MgCl 2 , 2 mM DTT, 1 tablet in 10 ml Complete EDTA-free protease inhibitor (Roche)), then passing through a 26 gauge needle 33, then spinning 10 min at 4 uC at 16,000g. Concentrated lysate was diluted 1:100 in 13 hypotonic lysis buffer and immediately assayed with 500 mM final PEP, 600 mM final ATP, 180 mM final NADH, and 0.16 mg ml 21 LDH in 13 reaction buffer (50 mM Tris pH 7.5, 50 mM KCl, 1 mM DTT) in 100 ml total. Decrease in NADH fluorescence was followed in a Tecan plate reader and a regression on the slope of the decrease was taken as the activity. Bradford assay was performed on the concentrated lysate and activities were normalized to total protein. Mitochondrial isolation and glycine cleavage assay. Intact mitochondria were isolated from mechanically lysed cells using differential centrifugation as described 41 , and the intact state of mitochondria verified using the JC-1 dye. Equal quantities of isolated mitochondria were resuspended in a buffer to support glycine cleavage activity as described 42 (100 mM KCl, 50 mM mannitol, 20 mM sucrose, 10 mM KH 2 PO 4 , 0.1 mM EGTA, 1 mM MgCl 2 , 0.175 mM pyridoxal phosphate, 1 mM ADP, 25 mM HEPES, pH 7.4) with the addition of 1 mM NAD1, 2 mM tetrahydrofolate, and 10 mM beta-mercaptoethanol. Upon addition of U-14 C serine, the reaction mixture containing mitochondria were incubated for 40 min at 37 uC, and CO 2 produced by the reactions were collected in phenylethylamine-coated paper overnight at 30 uC, and the 14 C content was measured using a scintillation counter. Statistics and animal models. All experiments reported in Figs 1-4 were repeated at least three times, except Figs 1f, 1k, 2b , and 4c, which were repeated twice; Figs 1c, 2a, 2f , and 4a were performed once. In addition, histological analyses experiments (Fig. 3c) and xenograft based experiments (Figs 1h-j, 3g, 4g) were performed once, with n's indicating the number of individual patient-based tumours or xenograft tumours. All centre values shown in graphs refer to the mean. t-tests were heteroscedastic to allow for unequal variance and distributions assumed to follow a Student's t distribution, and these assumptions are not contradicted by the data. No samples or animals were excluded from analysis, and sample size estimates were not used. Animals were randomly assigned to groups. Studies were not conducted blind with the exception of Fig. 3g a, SHMT2 and GLDC expression across GBM and normal brain regions as examined in autopsy sections. A whole coronal section is shown, with the GBM bulk tumour outlined in white. Insets indicate magnified micrographs from the regions, indicated by the small red squares, from the same brain. For the bulk tumour insets, cells around the pseudopalisading necroses are shown. Scale bars for whole coronal section 5 1 cm, and for insets 5 100 mm. b, SHMT2 expression at the GBM-normal brain interface, showing SHMT2-immunoreactivity in migrating cells. Scale bar, 100 mm. c, Magnified image of the boxed region in b. d, e, High-magnification micrographs of SHMT2 and GLDC expression, respectively, in (1) perinecrotic GBM tumour, (2) nonischaemic bulk tumour, (3) frontal cortex, (4) temporal white matter, and (5) striatum from autopsy cases. Scale bar, 100 mm. f, Semi-quantitative scoring of GLDC staining intensity by neuropathologist (M.S.) on 7 tumour biopsy cases (left) and 7 autopsy cases (right). g, Semi-quantitative scoring of SHMT2 staining intensity by neuropathologist (M.S.) on 7 tumour biopsy cases (left) and 7 autopsy cases (right). h, Viability of LN229 cells expressing an empty vector control or mouse GLDC cDNA and cultured in 0.5% hypoxia for 8 days.
Values are relative to that of the same cells cultured in parallel in normoxia. i, Cell number counts from LN229 cells expressing an empty vector control or SHMT2 cDNA and cultured in 0.5% hypoxia for 8 days. Values are relative to the counts of the same cells cultured in parallel in normoxia. j, Viability of U251 cells expressing shRNA or cDNAs as indicated and cultured in 0.5% hypoxia for 6 days. Values are relative to that of the same cells cultured in parallel in normoxia. For f and g, bars indicate the mean. For h-j, n 5 3 independent biological replicates; error bars are s.d. *P , 0.05 (Student's t-test). 5 4 technical replicates) . c, Pyruvate kinase activity assay from lysates of U251 cells transduced with indicated shRNAs or cDNAs. d, Proposed mechanism by which SHMT2 inhibition could lead to an increase in AICAR and SAICAR. In cells with high SHMT2 expression, 10-formyltetrahydrofolate, which is a downstream product of SHMT2 activity, serves as a cofactor for cytosolic 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ATIC) in the conversion of AICAR to FAICAR during purine biosynthesis. In the absence of SHMT2, a lack 10-formyltetrahydrofolate production could lead to accumulation of AICAR and SAICAR. As indicated by the asterisk, the contribution of SHMT2 to cytosolic 10-formyltetrahydrofolate formation may be direct, occur via export of formate from the mitochondria, or occur indirectly by changing serine/glycine levels and thereby altering SHMT1 activity. e, 13 C labelling rates of pyruvate and its downstream metabolites in cells from h. Labelling rates are relative and expressed as fold changes in cells transduced with shSHMT2_1 versus cells transduced with shGFP, with or without RNAi-resistant SHMT2 cDNA. Estimated PK flux is the calculated total flux to the four product species in moles of 13 C per unit time. Plots for individual labelled species over time are shown in g and Supplementary Table 9 . f, Scheme for calculating total PK flux by measuring the net molar labelling of U-[ 13 C]glucose derived, PK product species. Estimated PK flux is the calculated total flux to the four product species in moles of 13 C per unit time. g, Plots of glucose-derived labelled species abundance over time for shGFP, shSHMT2, and shGFP plus PKM2 cDNA expressing LN229 cells shown in Fig. 4e-g . Raw data, calculations and plots for all stable cell lines are shown in Supplementary data Tables 8 and 9 . h, SHMT2 and PKM2 expression in LN229 cells transduced with shRNAs and cDNAs as indicated. Asterisk indicates the overexpressed PKM2, which shows higher migration due to Flag tag. i, Oxygen consumption in LN229 cells expressing shGFP or shSHMT2_1 in RPMI media with or without 1 mM pyruvate. Error bars are s.d. (n 5 4 technical replicates). j, Viability of LN229 cells transduced with shRNAs or cDNAs as indicated, and also treated with vehicle or 50 mM of TEPP-46 or DASA-58 as indicated, then subjected to hypoxia for 6 days. Values are relative to the same cells grown in parallel in normoxia. k, Overview of effects of SHMT2 expression on cell metabolism, tumour cell survival, and liability to toxic glycine accumulation. Red arrow indicates upregulation, and blue arrow indicates downregulation. Grey bar indicates the inhibitory effect of SHMT2 activity on PKM2 activity. Depiction of pseudopalisading necrosis is adapted from ref. 43 , Nature Publishing Group. Illustration by Mica Duran. For a, c, e, g, and j, n 5 3 independent biological replicates; error bars are s.d. *P , 0.05 (Student's t-test).
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